Top Markets
Coin of the day
Immatics biotechnologies GmbH Immatics biotechnologies GmbH

Immatics biotechnologies GmbH

IMTXW
Peringkat dalam Saham #40870
Immatics N.V. operates as a clinical-stage biopharmaceutical firm dedicated to... Immatics N.V. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T cell-redirecting immunotherapies designed to combat cancer, primarily targeting the United States market for treatment applications. Their research and development efforts are concentrated on creating targeted immunotherapies for solid tumors, employing two distinct therapeutic strategies: adoptive cell therapies (ACTs) and antibody-like T-cell receptor (TCR) Bispecifics. Immatics N.V. boasts a robust pipeline of product candidates. Among these are IMA203, an immunotherapy targeting solid tumors, and IMA203CD8, a cell therapy product, both currently undergoing Phase 1b clinical trials. Additionally, their earlier-stage assets include IMA204, designed to target tumor stroma, and IMA30x, an allogeneic cellular therapy candidate, both of which are in preclinical development. The company is also progressing with its TCR Bispecifics portfolio, featuring IMA401 in Phase 1b clinical trials, alongside IMA402 and IMA403, which are presently in preclinical phases. Furthermore, Immatics N.V. has established strategic alliances to bolster its development efforts. These include a partnership with MD Anderson Cancer Center for the advancement of various T cell and TCR-based adoptive cellular therapies, an agreement with Celgene Corporation focused on creating innovative adoptive cell therapies for diverse cancers, and a collaboration with Genmab A/S aimed at developing T cell-engaging bispecific immunotherapies for multiple oncological indications. The company's corporate headquarters are situated in TΓΌbingen, Germany.
Harga Saham
$0.0006
Terakhir disinkronkan: 2025-06-30
Kapitalisasi Pasar
$69.91K
Perubahan (1 hari)
-88.46%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Immatics biotechnologies GmbH (IMTXW)

Kategori

Jumlah saham beredar untuk Immatics biotechnologies GmbH (IMTXW)
Jumlah saham beredar per August 2026: 0
Menurut laporan keuangan terbaru dan harga saham Immatics biotechnologies GmbH, jumlah saham beredar saat ini adalah 0. Pada akhir August 2026, perusahaan memiliki 0 saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Immatics biotechnologies GmbH (IMTXW) dari 2026 hingga 2026
Saham beredar pada akhir setiap tahun
Tahun Saham Beredar Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Saham beredar untuk perusahaan serupa atau pesaing
Perusahaan Saham Beredar Perbedaan Negara
253.90M -
US
62.19M -
NL
- -
CH
- -
KR
0.00 -
BE